Clinical development failure
Drug candidates may not demonstrate acceptable efficacy, safety, or tolerability.
- Scope
- TERN-701, TERN-501, TERN-800 series
- Materiality
- high
Terns Pharmaceuticals, Inc.
Terns Pharmaceuticals, Inc. is a U.S.-based clinical-stage biopharmaceutical company focused on discovering and developing small-molecule medicines for oncology and metabolic diseases. Its pipeline includes internally discovered drug candidates such as TERN-701 and TERN-501, along with the TERN-800 series of GIPR modulators for obesity.
62.41
62.41
| % | |
|---|---|
| Oncology pipeline | 0% Small-molecule drug candidates for cancer treatment, including TERN-701 and TERN-501. |
| Metabolic disease pipeline | 0% Obesity-focused programs built around GIPR modulation and combination approaches. |
| Discovery and preclinical development | 0% Internal discovery, preclinical research, and candidate nomination activities. |
| Clinical development | 0% Human clinical testing and related regulatory development for pipeline assets. |
| Out-licensing and partnering | 0% Potential milestone-based collaboration and license arrangements for select programs. |
Terns does not sell commercial products; its direct counterparties are primarily pharmaceutical partners, contract...
- Strategic pharmaceutical partnersprimary
Potential licensees or collaborators that may fund or regionalize development of TERN-701 or metabolic assets.
- CRO and CMO vendorsprimary
Service providers that support discovery, manufacturing, and clinical execution.
- Regulatory agenciesprimary
FDA and foreign regulators that review INDs, trial plans, and marketing applications.
- Future oncology patientsemerging
Patients who would ultimately receive TERN-701 or related oncology therapies if approved.
- Future obesity patientsemerging
Patients who would ultimately receive GIPR-based metabolic therapies if approved.
Terns is headquartered in the United States, but its development footprint is international because clinical trials,...
- •United States headquarters and primary corporate operations
- •Clinical development and regulatory interactions centered in the U.S.
- •China exposure through suppliers, trials, and a greater China license
- •Europe and other countries used for global trial execution
- •Canada and other international jurisdictions in the supply chain
Terns is prioritizing advancement of its oncology lead program, especially TERN-701, while maintaining a selective...
01
Advance TERN-701short-term
The company views this as its most important internal program and a key value driver.
02
Partner selected programsshort-term
Partnerships can provide external funding, regional reach, and development support.
03
Build obesity pipeline selectivelymedium-term
GIPR modulation may create combination opportunities with GLP-1 therapies.
Terns faces the typical risks of a clinical-stage biotech company: clinical failure, regulatory delay, and dependence...
Regulatory delay or disruption
FDA and foreign agency disruptions can slow guidance, review, and approvals.
- Scope
- INDs, clinical trials, marketing applications
- Materiality
- high
China trade and supply-chain exposure
Manufacturers, suppliers, and trial activity in China can be affected by tariffs, sanctions, or export restrictions.
- Scope
- Contract manufacturers, global trials, greater China licensing
- Materiality
- high
Funding dependence
The company has no product revenue and relies on external financing to fund development.
- Scope
- Operating runway and trial execution
- Materiality
- high
Partnering and commercialization risk
Potential collaborators may demand favorable economics or decline to partner if competing assets look stronger.
- Scope
- TERN-601, TERN-501, TERN-800 series
- Materiality
- medium
Research and development accruals
Can shift operating loss between periods
License and milestone revenue
Could create lumpy revenue recognition
Stock-based compensation
Affects G&A expense and equity dilution
Capitalized prepayments and trial costs
Affects timing of expense recognition
Traws Pharma, Inc.
TRAW · Pharmaceutical Preparations
IONIS PHARMACEUTICALS INC
IONS · Pharmaceutical Preparations
Ionis Pharmaceuticals is a U.S.-based biotechnology company focused on RNA-targeted medicines, using antisense chemistry to discover and develop therapies for serious diseases.
Seres Therapeutics, Inc.
MCRB · Pharmaceutical Preparations
Keros Therapeutics, Inc.
KROS · Pharmaceutical Preparations
Keros Therapeutics is a clinical-stage biopharmaceutical company developing protein therapeutics for disorders driven by dysfunctional TGF-β family signaling.
Corvus Pharmaceuticals, Inc.
CRVS · Pharmaceutical Preparations
TerrAscend Corp.
TSNDF · Agricultural Production-Crops
: 29.4.2026